Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others) and by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies) was valued US$ 370.4 million in 2017 and is estimated to exhibit a CAGR of 4.8% over the forecast period (2018-2026).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1965
Scopolamine is a prescription drug, which is used for the treatment of muscle spasms, Parkinson’s disease, vomiting, irritable bowel syndrome, nausea, and dizziness that often accompanies motion sickness. Moreover, scopolamine is a completely legal drug prescribed by health care providers, however it is used for several unlawful purposes in various economies such as the U.K. and Colombia. Scopolamine is also commonly known as Devil’s Breath or burundanga. For instance, it made headlines around the world in 2012, when at least 1,200 known cases was reported about the drug being used to force people including politicians into doing illegal things in Canada, Australia, and Colombia.
Usage of scopolamine in Alzheimer’s disease may prove useful as a diagnostic or staging test in the evaluation of the cholinergic system in dementia, which offers opportunities to the researchers to explore application of these drugs for other neurological disorders, which is further expected to drive the market growth over the forecast period.
Browse 19 Market Data Tables and 23 Figures spread through 151 Pages and in-depth TOC on “Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Forecast to 2026”
To know the latest trends and insights related to scopolamine market Press Release, click the link below: https://bit.ly/2ZPoLoh
Key market players are focusing on developing new generics through partnerships to expand their product portfolio, and to strengthen their position in the global market. For instance, Perrigo Company plc. and its co-development partner Aveva Drug Delivery Systems, Inc., launched scopolamine 1.5 mg transdermal system patch, generic equivalent to GlaxoSmithKline’s Transderm Scop (scopolamine 1.5 mg), in 2017. This transdermal system patch is indicated for prevention of nausea and vomiting in adults associated with motion sickness, and recovery from anesthesia and/or opiate analgesia and surgery.
Moreover, the annual U.S. market sales/revenue for Transderm Scop was US$ 158 million in the 12 months ending in May 2017.
Key Takeaways of the Scopolamine Market:
- The global scopolamine market is expected to exhibit a CAGR of 4.8% over the forecast period (2018-2026), attributed to increasing adoption of scopolamine in surgeries and post-operative recovery
- Among dosage form, patches segment is expected to account for major market share in the market over the forecast period, owing to utilization of these patches in surgeries to prevent hyper salivation and to speed-up the recovery from post-operative and anesthesia induced vomiting, and nausea
- Key players operating in global scopolamine market include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1965
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
